Literature DB >> 16136388

Surveillance in Lynch syndrome.

Jukka-Pekka Mecklin1, Heikki J Järvinen.   

Abstract

The major aim of surveillance in Lynch syndrome is to diagnose malignant or premalignant lesions at the asymptomatic stage by regular checkups, particularly in the large bowel. Therefore, screening for colorectal adenomas and carcinomas by regular colonoscopies is the main topic of the present review. However, it should be remembered, that primary prevention - whether through the use of chemoprevention or the promotion of a healthy life-style may form a significant part of such surveillance in the future. Observational studies indicate that the adenoma carcinoma sequence is the main pathway in the development of colorectal cancer in Lynch syndrome. A colonoscopy every 1-3 years starting at age 20 to 25 years and the removal of observed adenomas is recommended for individuals known to have Lynch syndrome associated mutations. The incidence of colorectal cancer in family branches screened this way is lower than that in past unscreened generations. The screening of other malignancies associated with Lynch syndrome is more complex. Screening for endometrial cancer has recommended previously, but no benefits have been shown in recent studies. The value of screening for other extracolonic cancers remains also uncertain.

Entities:  

Mesh:

Year:  2005        PMID: 16136388     DOI: 10.1007/s10689-005-1475-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  40 in total

1.  Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction.

Authors:  K Aktan-Collan; J P Mecklin; H Järvinen; M Nyström-Lahti; P Peltomäki; I Söderling; A Uutela; A de la Chapelle; H Kääriäinen
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

2.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

Review 3.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.

Authors:  W Burke; G Petersen; P Lynch; J Botkin; M Daly; J Garber; M J Kahn; A McTiernan; K Offit; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

4.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Authors:  R K S Phillips; M H Wallace; P M Lynch; E Hawk; G B Gordon; B P Saunders; N Wakabayashi; Y Shen; S Zimmerman; L Godio; M Rodrigues-Bigas; L-K Su; J Sherman; G Kelloff; B Levin; G Steinbach
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

5.  Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.

Authors:  Elise Renkonen; Yange Zhang; Hannes Lohi; Reijo Salovaara; Wael M Abdel-Rahman; Mef Nilbert; Kristiina Aittomaki; Heikki J Jarvinen; Jukka-Pekka Mecklin; Annika Lindblom; Paivi Peltomaki
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

6.  Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum.

Authors:  Claudio Soravia; Heleen van der Klift; Marie-Anne Bründler; Jean-Louis Blouin; Juul Wijnen; Pierre Hutter; Riccardo Fodde; Célia Delozier-Blanchet
Journal:  Am J Med Genet A       Date:  2003-08-30       Impact factor: 2.802

7.  The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.

Authors:  H F Vasen; P Watson; J P Mecklin; J R Jass; J S Green; T Nomizu; H Müller; H T Lynch
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

8.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

10.  Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer.

Authors:  K M Lin; M Shashidharan; A G Thorson; C A Ternent; G J Blatchford; M A Christensen; P Watson; S J Lemon; B Franklin; B Karr; J Lynch; H T Lynch
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.267

View more
  7 in total

1.  The management of families affected by hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  Johanne Geary; Huw J W Thomas; James Mackay; Huw Dorkins; Julian Barwell; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

2.  Magnetic resonance colonography for colorectal cancer screening in patients with Lynch syndrome gene mutation.

Authors:  Eu Jin Lim; Christopher Leung; Alex Pitman; Damien L Stella; Gregor Brown; Masha Slattery; Kaye Marion; Finlay Macrae
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 3.  TGF-beta signaling alterations and susceptibility to colorectal cancer.

Authors:  Yanfei Xu; Boris Pasche
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

4.  Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x.

Authors:  Mev Dominguez-Valentin; Christina Therkildsen; Srinivas Veerla; Mats Jönsson; Inge Bernstein; Ake Borg; Mef Nilbert
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome.

Authors:  Mev Dominguez-Valentin; Patrik Wernhoff; Andrea R Cajal; Pablo G Kalfayan; Tamara A Piñero; Maria L Gonzalez; Alejandra Ferro; Ines Sammartino; Natalia S Causada Calo; Carlos A Vaccaro
Journal:  Front Oncol       Date:  2016-08-24       Impact factor: 6.244

6.  MUTYH Associated Polyposis (MAP).

Authors:  M L M Poulsen; M L Bisgaard
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

7.  Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.

Authors:  Neil A J Ryan; Julie Morris; Kate Green; Fiona Lalloo; Emma R Woodward; James Hill; Emma J Crosbie; D Gareth Evans
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.